Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most
common type being venous thromboembolism (VTE). Several risk factors for developing …

Venous thromboembolism (VTE) is a frequent and potentially life-threatening complication
associated with hematological and solid tumor malignancies. In patients with cancer, VTE …

Immune checkpoint inhibitors (ICIs) target programmed cell death (PD) 1 receptor and its
ligand PD-L1, and have become an integral part of treatment regimens in many cancers …

In patients with solid tumours or haematological malignancies, venous thromboembolism
(VTE) is a leading cause of death and significantly contributes to morbidity and healthcare …

Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in patients
with cancer. The risk of VTE varies over the natural history of cancer, with the highest risk …

Venous thromboembolism (VTE) is an increasingly frequent complication of anticancer
therapy. The underlying mechanisms are not completely understood, but are related in part …

Background Venous thromboembolism (VTE) is a major cause of death in cancer patients.
Although patients with cancer have numerous risk factors for VTE, the relative contribution of …

Venous thromboembolism (VTE) is a potentially life-threatening condition that can be
associated with significant morbidity. Thrombosis and cancer are linked by numerous …

Purpose Patients with cancer are increasingly at risk for venous thromboembolism (VTE).
Rates of VTE, however, vary markedly among patients with cancer. Design This review …